Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies.


iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs.


iSPERSE can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.

Benefits of

iSPERSE™ White


Can be used with a broad range of drugs, small molecule to biologic


Can deliver large doses into lungs (tens of milligrams) with high lung delivery efficiency


Can be used with almost any device (ie, metered-dose, reservoir, or blister-based inhalers)


Avoids first-pass effect and systemic side-effects, with improved PK profile compared to oral delivery


Requires low inspiratory flow for penetration deep into lung, based on high dispersibility


Broad IP portfolio into 2030s


PULMATRiX is currently
studying the potential for iSPERSE
to improve the lives of patients living with:

Bronchopulmonary Aspergillosis

Learn about

Acute Exacerbations
in Chronic Obstructive
Pulmonary Disease

Learn about


AK Curran and DL Hava. 2021. Allergic diseases caused by Aspergillus
species in patients with cystic fibrosis. Antibiotics 10: 357.

DL Hava, L Tan, P Johnson, AK Curran, J Perry, S Kramer, K Kane,
P Bedwell, G Layton, C Swann, D Henderson, N Khan, L Connor,
L McKenzie, D Singh, and J Roach. 2020. A phase 1/1b study of
PUR1900, an inhaled formulation of itraconazole, in healthy
volunteers and asthmatics to study safety, tolerability and
pharmacokinetics. British Journal of Clinical Pharmacology 86: 723–733.

D Edwards, A Hickey, R Batycky, L Griel, M Lipp, W Dehaan, R Clarke,
DL Hava, J Perry, B Laurenzi, AK Curran, BJ Beddingfield,
C Roy, T Devlin, and R Langer. 2020. A new natural defense
against airborne pathogens. QRB Discovery: 1–28.

J Perry, B Trautman, J Takher‐Smith, S Kramer, K Kane, M Silverman,
L Tan, S Haughie, W Richter, V Kirkov, S Arsova, J Ward, and
DL Hava. 2019. Particle size and gastrointestinal absorption
influence tiotropium pharmacokinetics: a pilot bioequivalence
study of PUR0200 and Spiriva HandiHaler. British Journal of
Clinical Pharmacology 85: 580–589.

PW Andreotta, S Arold, J Kenyon, D Spicer, P Woodman, E Berry,
T Brogan, S Kong, P Okerholm, V Russell, RW Clarke, and DL Hava.
2018. Inhaled calcium salts inhibit tobacco smoke-induced
inflammation by modulating expression of chemokines and cytokines.
Pulm Pharmacol Ther 53: 86–99.

D Singh, A Ravi, K Kane, T Schmalbach, and DL Hava. 2018.
The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a
novel tiotropium formulation, in chronic obstructive pulmonary disease.
British Journal of Clinical Pharmacology 84: 2097–2105.

KA Provost, M Smith, SP Arold, DL Hava, and S Sethi. 2015. Calcium restores the macrophage response to nontypeable haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 52: 728–737.

O Holz, H Biller, M Mueller, K Kane, M Rosano, J Hanrahan, DL Hava, and JM Hohlfeld. 2015. Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial. BMC Pharmacology and Toxicology 16.


As we advance our mission to develop and commercialize novel and transformational medicines, we regularly share the progress of our research.

To learn more about our science and research findings, download these PDFs:

AAAAI 2023 - Safety and Tolerability of PUR1800, an Orally Inhaled Narrow Spectrum Kinase Inhibitor, in Patients with Stable Chronic Obstructive Pulmonary Disease (COPD) / PDF

AHS 2023 - A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, a Novel Dry Powder Formulation of DHE for Oral Inhalation, in Healthy Adults / PDF

ACAAI 2018 – A phase 1/1b study of an inhaled formulation of itraconazole in healthy volunteers and asthmatics / PDF

NACF2017 – Systemic and pulmonary exposure of PUR1900 following inhalation dosing in rats and dogs over 28 days / PDF

NACFC 2016 – Pulmonary delivery of PUR1900 enables high lung exposure of Itraconazole relative to oral dosing / PDF

RDD 2014 — Levofloxacin Dry Powders Engineered for Efficient Pulmonary Delivery and Stability / PDF

RDD 2012 — Development of an iSPERSE™ Based Platform for the Delivery of Macromolecules via Dry Powder Formulations / PDF

RDD 2012 — Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology / PDF

ATS 2012 — A Novel Inhaled Dry Powder Delivery Platform for the Delivery of Large Molecule Drugs to the Lung for Local and Systemic Treatments / PDF

RDD Europe 2011 — iSPERSE™: Formulation and In Vitro Characterization of a Novel Dry Powder Drug Delivery Technology / PDF

ATS 2011 — Efficacy of Fluticasone and Salmeterol in a Novel Inhaled Dry Powder Delivery Platform / PDF

ISAM 2011 Conference abstract — Deposition of Aerosolized Liquid Formulation in Ferrets by 3D CT / Spect Imaging / PDF

ISAM 2011 Conference abstract — A Novel Inhaled Dry Powder Delivery Platform; Efficacy of Fluticasone and Salmeterol During Allergic Asthma / PDF